NCT05996185
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma treatment 2 not_yet_recruiting NCT02588651
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) treatment 2 active_not_recruiting NCT05442554
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma treatment 4 completed NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available active_not_recruiting NCT05983965
Study of Tazemetostat in Lymphoid Malignancies treatment 1 recruiting NCT04712864
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma No drug interventions treatment 1 active_not_recruiting NCT00161590
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma treatment 1 completed NCT06224049
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T treatment 0 recruiting NCT04264078
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies treatment 0 unknown_status NCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT02424045
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma treatment 2 completed NCT02017613
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies No drug interventions treatment 1 completed NCT01902225
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma treatment 1 completed NCT01777152
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas treatment 3 completed NCT01553786
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) treatment 2 completed NCT01181271
Tandem Auto-Allo Transplant for Lymphoma treatment 2 completed NCT00893516
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma No drug interventions treatment 2 terminated NCT00542919
A Study for Patients With Non-Hodgkin's Lymphomas treatment 2 completed NCT00322985
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT00161239
LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma treatment Not Available terminated NCT05367856
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma treatment 2 recruiting NCT04653649
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. No drug interventions treatment 1 / 2 unknown_status NCT01430013
Trial of Endostar Combined With CHOPT for T Cell Lymphoma treatment 2 unknown_status NCT00974324
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma treatment 2 unknown_status NCT05075460
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma treatment 3 recruiting NCT05731375
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage No drug interventions Not Available Not Available not_yet_recruiting NCT03952078
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma treatment 1 active_not_recruiting NCT03792256
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) treatment 1 active_not_recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT05886478
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin Not Available Not Available recruiting NCT02086591
A Phase II Study of Doxycycline in Relapsed NHL treatment 2 terminated NCT01878708
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma treatment 0 terminated NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies treatment 1 completed NCT01300026
AMG 319 Lymphoid Malignancy FIH No drug interventions treatment 1 completed NCT04334174
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas treatment 2 withdrawn NCT04973527
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor No drug interventions treatment 1 terminated NCT06420076
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells No drug interventions treatment 1 / 2 recruiting NCT05230680
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) No drug interventions treatment 1 / 2 recruiting NCT03672084
Allo-HSCT as First-line Consolidation in High-risk PTCL No drug interventions Not Available Not Available unknown_status NCT01561833
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients treatment 1 completed NCT05852028
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma Not Available Not Available recruiting NCT05772728
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) treatment Not Available not_yet_recruiting NCT00877656
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma treatment 2 / 3 completed NCT03770000
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma treatment 1 / 2 completed NCT04840875
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma No drug interventions treatment 1 recruiting NCT05978141
A Registry for People With T-cell Lymphoma No drug interventions Not Available Not Available recruiting NCT05387226
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma No drug interventions treatment 1 unknown_status NCT05313243
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma treatment 2 recruiting NCT04331119
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas treatment 2 active_not_recruiting NCT03207789
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients No drug interventions Not Available Not Available unknown_status NCT03829540
CD4CAR for CD4+ Leukemia and Lymphoma No drug interventions treatment 1 recruiting NCT02846935
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies treatment 0 completed NCT03021057
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas treatment 2 unknown_status NCT02309580
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma treatment 1 completed NCT01941680
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant No drug interventions Not Available Not Available completed NCT01854112
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT00959686
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma treatment 2 completed NCT00001582
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer No drug interventions Not Available Not Available completed NCT00798096
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma treatment 2 completed NCT00880867
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma treatment 1 terminated NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT04502446
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) treatment 1 active_not_recruiting NCT03628612
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells No drug interventions other 2 enrolling_by_invitation NCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma treatment 1 active_not_recruiting NCT00840385
Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) treatment 2 unknown_status NCT01685606
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma No drug interventions treatment 2 terminated NCT02341014
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas treatment 1 / 2 completed NCT00611208
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) treatment 2 completed NCT06390319
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) treatment 2 not_yet_recruiting NCT06561048
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma treatment 3 recruiting NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma No drug interventions treatment 1 unknown_status NCT04928105
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma No drug interventions treatment Not Available unknown_status NCT04233697
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma other 1 withdrawn NCT00038883
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies treatment Not Available terminated NCT04121507
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy screening 2 completed NCT04136275
CAR-37 T Cells In Hematologic Malignancies No drug interventions treatment 1 completed NCT02158975
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas treatment 2 completed NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies treatment 1 recruiting NCT05466318
ChiCGB vs BEAM in High-risk or R/R Lymphomas treatment 3 recruiting NCT00082017
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas treatment 2 terminated NCT00418535
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma treatment 2 completed NCT05463263
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas No drug interventions treatment 1 / 2 recruiting NCT00038376
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies treatment 2 completed NCT01309789
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms treatment 1 completed NCT00043368
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) treatment 2 completed NCT06530550
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas No drug interventions treatment 2 recruiting NCT03161223
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma treatment 1 / 2 unknown_status NCT00069238
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas treatment 2 completed NCT05557903
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL No drug interventions treatment 1 unknown_status NCT03902184
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma treatment 2 active_not_recruiting NCT03703375
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma treatment 3 active_not_recruiting NCT04104776
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas No drug interventions treatment 1 / 2 recruiting NCT06534060
MB-105 in Patients With CD5 Positive T-cell Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT05540340
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant No drug interventions treatment 1 recruiting NCT01421667
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT03154710
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response No drug interventions diagnostic Not Available terminated NCT05398614
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies No drug interventions treatment 1 unknown_status NCT03910283
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer No drug interventions supportive_care Not Available not_yet_recruiting